RxDoctor Payments Data

Mario Rojas, MD

Ophthalmology · Coral Gables, FLNPI 1659634939

Payments from drug & device makers

$14,117in general payments, 2019–2025

Across 386 payments — averaging $36.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Alcon$2K
  • NEW World Medical,inc.$1K
  • Bausch & Lomb Americas Inc.$970
  • Sight Sciences, Inc.$861
  • Biotissue Holdings Inc.$585
  • plus $4K from 20 others

What the payments were for

  • Food & beverage$14,100100%
  • Gifts$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,117 in reported general payments places this provider in the 80th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$23,419
Medicare patients
92
Services billed
172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost1,213$397,546
XiidraLifitegrast257$255,526
CequaCyclosporine311$233,874
RestasisCyclosporine182$180,565
CombiganBrimonidine Tartrate/Timolol309$100,949
RhopressaNetarsudil Mesylate294$99,435
RocklatanNetarsudil Mesylat/Latanoprost202$78,014
Alphagan PBrimonidine Tartrate183$62,808
Prednisolone Acetate1,809$58,083
EysuvisLoteprednol Etabonate107$52,261
VyzultaLatanoprostene Bunod158$44,817
IlevroNepafenac122$44,564
VevyeCyclosporine41$30,448
MoxifloxacinMoxifloxacin Hcl914$29,197
Bromfenac Sodium228$22,386

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$3,843$741,8671,887 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo$970$311,624430 claims
Sun Pharmaceutical Industries Inc.Cequa$397$233,874311 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$424$177,449496 claims
NovartisIlevro$350$44,564122 claims
Harrow Eye, LLCVevye$236$30,44841 claims
AlconSimbrinza$2,397$22,243105 claims
Oyster Point Pharma, Inc.Tyrvaya$535$18,73528 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$339$13,11836 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Coral Gables

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →